145 related articles for article (PubMed ID: 35740244)
1. Preclinical Studies of Granulysin-Based Anti-MUC1-Tn Immunotoxins as a New Antitumoral Treatment.
Guerrero-Ochoa P; Ibáñez-Pérez R; Berbegal-Pinilla G; Aguilar D; Marzo I; Corzana F; Minjárez-Sáenz M; Macías-León J; Conde B; Raso J; Hurtado-Guerrero R; Anel A
Biomedicines; 2022 May; 10(6):. PubMed ID: 35740244
[TBL] [Abstract][Full Text] [Related]
2. Production of a Granulysin-Based, Tn-Targeted Cytolytic Immunotoxin Using Pulsed Electric Field Technology.
Guerrero-Ochoa P; Aguilar-Machado D; Ibáñez-Pérez R; Macías-León J; Hurtado-Guerrero R; Raso J; Anel A
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32859066
[TBL] [Abstract][Full Text] [Related]
3. Conjugation of the 9-kDa Isoform of Granulysin with Liposomes Potentiates Its Cytotoxicity.
Soler-Agesta R; Guerrero-Ochoa P; Marco-Brualla J; Ibáñez-Pérez R; Marzo I; Martínez-Lostao L; Anel A
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955839
[TBL] [Abstract][Full Text] [Related]
4. Characterization of an anti-MUC1 monoclonal antibody with potential as a cancer vaccine.
Qi W; Schultes BC; Liu D; Kuzma M; Decker W; Madiyalakan R
Hybrid Hybridomics; 2001; 20(5-6):313-24. PubMed ID: 11839249
[TBL] [Abstract][Full Text] [Related]
5.
Fung K; Vivier D; Keinänen O; Sarbisheh EK; Price EW; Zeglis BM
Molecules; 2020 May; 25(10):. PubMed ID: 32429033
[TBL] [Abstract][Full Text] [Related]
6. Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicity.
Lavrsen K; Madsen CB; Rasch MG; Woetmann A; Ødum N; Mandel U; Clausen H; Pedersen AE; Wandall HH
Glycoconj J; 2013 Apr; 30(3):227-36. PubMed ID: 22878593
[TBL] [Abstract][Full Text] [Related]
7. Comparison of recombinant immunotoxins against LeY antigen expressing tumor cells: influence of affinity, size, and stability.
Bera TK; Pastan I
Bioconjug Chem; 1998; 9(6):736-43. PubMed ID: 9815167
[TBL] [Abstract][Full Text] [Related]
8. Structure-guided engineering of the affinity and specificity of CARs against Tn-glycopeptides.
Sharma P; Marada VVVR; Cai Q; Kizerwetter M; He Y; Wolf SP; Schreiber K; Clausen H; Schreiber H; Kranz DM
Proc Natl Acad Sci U S A; 2020 Jun; 117(26):15148-15159. PubMed ID: 32541028
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumoral potential of a human granulysin-based, CEA-targeted cytolytic immunotoxin.
Ibáñez-Pérez R; Guerrero-Ochoa P; Al-Wasaby S; Navarro R; Tapia-Galisteo A; De Miguel D; Gonzalo O; Conde B; Martínez-Lostao L; Hurtado-Guerrero R; Sanz L; Anel A
Oncoimmunology; 2019; 8(11):1641392. PubMed ID: 31646080
[TBL] [Abstract][Full Text] [Related]
10. Affinity-matured anti-glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas.
Kuan CT; Wakiya K; Keir ST; Li J; Herndon JE; Pastan I; Bigner DD
Int J Cancer; 2011 Jul; 129(1):111-21. PubMed ID: 20824708
[TBL] [Abstract][Full Text] [Related]
11. A Synthetic MUC1 Glycopeptide Bearing βGalNAc-Thr as a Tn Antigen Isomer Induces the Production of Antibodies against Tumor Cells.
Leiria Campo V; Riul TB; Oliveira Bortot L; Martins-Teixeira MB; Fiori Marchiori M; Iaccarino E; Ruvo M; Dias-Baruffi M; Carvalho I
Chembiochem; 2017 Mar; 18(6):527-538. PubMed ID: 28068458
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis.
Martínez-Torrecuadrada JL; Cheung LH; López-Serra P; Barderas R; Cañamero M; Ferreiro S; Rosenblum MG; Casal JI
Mol Cancer Ther; 2008 Apr; 7(4):862-73. PubMed ID: 18413799
[TBL] [Abstract][Full Text] [Related]
13. Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma.
Posey AD; Schwab RD; Boesteanu AC; Steentoft C; Mandel U; Engels B; Stone JD; Madsen TD; Schreiber K; Haines KM; Cogdill AP; Chen TJ; Song D; Scholler J; Kranz DM; Feldman MD; Young R; Keith B; Schreiber H; Clausen H; Johnson LA; June CH
Immunity; 2016 Jun; 44(6):1444-54. PubMed ID: 27332733
[TBL] [Abstract][Full Text] [Related]
14. Lack of polymorphism in MUC1 tandem repeats in cancer cells is related to breast cancer progression in Japanese women.
Kawaguchi T; Takazawa H; Imai S; Morimoto J; Watanabe T
Breast Cancer Res Treat; 2005 Aug; 92(3):223-30. PubMed ID: 16155793
[TBL] [Abstract][Full Text] [Related]
15. A novel Carcinoembryonic Antigen (CEA)-Targeted Trimeric Immunotoxin shows significantly enhanced Antitumor Activity in Human Colorectal Cancer Xenografts.
Lázaro-Gorines R; Ruiz-de-la-Herrán J; Navarro R; Sanz L; Álvarez-Vallina L; Martínez-Del-Pozo A; Gavilanes JG; Lacadena J
Sci Rep; 2019 Aug; 9(1):11680. PubMed ID: 31406218
[TBL] [Abstract][Full Text] [Related]
16. Selective cytotoxicity to HER2-positive tumor cells by a recombinant e23sFv-TD-tBID protein containing a furin cleavage sequence.
Wang F; Ren J; Qiu XC; Wang LF; Zhu Q; Zhang YQ; Huan Y; Meng YL; Yao LB; Chen SY; Xu YM; Yang AG
Clin Cancer Res; 2010 Apr; 16(8):2284-94. PubMed ID: 20371697
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity.
de Bono JS; Rha SY; Stephenson J; Schultes BC; Monroe P; Eckhardt GS; Hammond LA; Whiteside TL; Nicodemus CF; Cermak JM; Rowinsky EK; Tolcher AW
Ann Oncol; 2004 Dec; 15(12):1825-33. PubMed ID: 15550589
[TBL] [Abstract][Full Text] [Related]
18. Glycosylation of MUC1 influences the binding of a therapeutic antibody by altering the conformational equilibrium of the antigen.
Movahedin M; Brooks TM; Supekar NT; Gokanapudi N; Boons GJ; Brooks CL
Glycobiology; 2017 Jul; 27(7):677-687. PubMed ID: 28025250
[TBL] [Abstract][Full Text] [Related]
19. COSMC knockdown mediated aberrant O-glycosylation promotes oncogenic properties in pancreatic cancer.
Hofmann BT; Schlüter L; Lange P; Mercanoglu B; Ewald F; Fölster A; Picksak AS; Harder S; El Gammal AT; Grupp K; Güngör C; Drenckhan A; Schlüter H; Wagener C; Izbicki JR; Jücker M; Bockhorn M; Wolters-Eisfeld G
Mol Cancer; 2015 May; 14():109. PubMed ID: 26021314
[TBL] [Abstract][Full Text] [Related]
20. Antigen binding and cytotoxic properties of a recombinant immunotoxin incorporating the lytic peptide, melittin.
Dunn RD; Weston KM; Longhurst TJ; Lilley GG; Rivett DE; Hudson PJ; Raison RL
Immunotechnology; 1996 Sep; 2(3):229-40. PubMed ID: 9373315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
